These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 32482309)

  • 1. A Meta-Analysis of Cardiovascular Outcomes in Patients With Hypercholesterolemia Treated With Inclisiran.
    Asbeutah AAA; Asbeutah SA; Abu-Assi MA
    Am J Cardiol; 2020 Aug; 128():218-219. PubMed ID: 32482309
    [No Abstract]   [Full Text] [Related]  

  • 2. Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia.
    Khan SA; Naz A; Qamar Masood M; Shah R
    Am J Cardiol; 2020 Nov; 134():69-73. PubMed ID: 32892993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9.
    German CA; Shapiro MD
    BioDrugs; 2020 Feb; 34(1):1-9. PubMed ID: 31782112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How far down to push the LDL cholesterol? PCSK9 where statins fail.
    Simko V; Ginter E
    Bratisl Lek Listy; 2016; 117(4):193-4. PubMed ID: 27075380
    [No Abstract]   [Full Text] [Related]  

  • 5. Inclisiran for the treatment of hypercholesterolaemia: implications and unanswered questions from the ORION trials.
    Cupido AJ; Kastelein JJP
    Cardiovasc Res; 2020 Sep; 116(11):e136-e139. PubMed ID: 32766688
    [No Abstract]   [Full Text] [Related]  

  • 6. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial.
    Arrieta A; Hong JC; Khera R; Virani SS; Krumholz HM; Nasir K
    JAMA Cardiol; 2017 Dec; 2(12):1369-1374. PubMed ID: 29049467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-Density Lipoprotein Cholesterol and Drug Treatment to Lower Atherosclerotic Cardiovascular Disease Risk: Where Do We Stand?
    Lloyd-Jones DM
    JAMA Cardiol; 2017 Sep; 2(9):937-938. PubMed ID: 28768306
    [No Abstract]   [Full Text] [Related]  

  • 8. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration.
    Ference BA; Cannon CP; Landmesser U; Lüscher TF; Catapano AL; Ray KK
    Eur Heart J; 2018 Jul; 39(27):2540-2545. PubMed ID: 29020411
    [No Abstract]   [Full Text] [Related]  

  • 9. New and Future Parenteral Therapies for the Management of Lipid Disorders.
    Garcia R; Burkle J
    Arch Med Res; 2018 Nov; 49(8):538-547. PubMed ID: 30739730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
    Ray KK; Landmesser U; Leiter LA; Kallend D; Dufour R; Karakas M; Hall T; Troquay RP; Turner T; Visseren FL; Wijngaard P; Wright RS; Kastelein JJ
    N Engl J Med; 2017 Apr; 376(15):1430-1440. PubMed ID: 28306389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience.
    Gragnano F; Natale F; Concilio C; Fimiani F; Cesaro A; Sperlongano S; Crisci M; Limongelli G; Calabrò R; Russo M; Golia E; Calabrò P
    J Cardiovasc Med (Hagerstown); 2018 Feb; 19(2):75-77. PubMed ID: 29251697
    [No Abstract]   [Full Text] [Related]  

  • 12. [New drug development competition for LDL receptor].
    Fujita T
    Nihon Yakurigaku Zasshi; 2014 May; 143(5):262. PubMed ID: 24813799
    [No Abstract]   [Full Text] [Related]  

  • 13. Statins and risk of new-onset diabetes mellitus.
    Shah RV; Goldfine AB
    Circulation; 2012 Oct; 126(18):e282-4. PubMed ID: 23109518
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
    Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular aspects of hypercholesterolemia treatment: current perspectives and hopes.
    Ahangari N; Ghayour Mobarhan M; Sahebkar A; Pasdar A
    Ann Med; 2018 Jun; 50(4):303-311. PubMed ID: 29578362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
    Schwartz GG; Bessac L; Berdan LG; Bhatt DL; Bittner V; Diaz R; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Mahaffey KW; Moryusef A; Pordy R; Roe MT; Rorick T; Sasiela WJ; Shirodaria C; Szarek M; Tamby JF; Tricoci P; White H; Zeiher A; Steg PG
    Am Heart J; 2014 Nov; 168(5):682-9. PubMed ID: 25440796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk.
    Milionis H; Barkas F; Ntaios G; Papavasileiou V; Vemmos K; Michel P; Elisaf M
    Eur J Intern Med; 2016 Oct; 34():54-57. PubMed ID: 27363304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
    Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G
    Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging biologic therapies for hypercholesterolaemia.
    Pucci G; Cicero AF; Borghi C; Schillaci G
    Expert Opin Biol Ther; 2017 Sep; 17(9):1077-1087. PubMed ID: 28617192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypercholesterolemia: The role of PCSK9.
    Melendez QM; Krishnaji ST; Wooten CJ; Lopez D
    Arch Biochem Biophys; 2017 Jul; 625-626():39-53. PubMed ID: 28587771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.